Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Detailed clinical characteristics and LOH analysis results of the 21 patients included in this study

From: Clonal relationship of synchronous head and neck cancer and esophageal cancer assessed by single nucleotide polymorphism-based loss of heterozygosity analysis

No.SexAge-rangesHNSCCESCCThis studyGeurts et al., 2005 [16]
SiteStageaSiteStagea%Discordant LOH%Concordant LOHRatioConclusionDiscordant LOHbConcordant LOHAll discordant LOHConclusion
1M56–60oropharynxT3 N0
M0
middleT2 N0 M095.454.5517.2SFT/SPM015SPM
2M61–65oropharynxT1 N0
M0
middleT2 N1 M056.2543.751.3Undetermined000?
3M61–65oropharynxT2 N1
M0
middleT2 N1 M01000100SPM202SPM
4M36–40larynxT3 N3
M0
middleT1 N0 M095.454.5517.2SFT/SPM505SPM
5M51–55larynxT1 N0
M0
middleT2 N1 M092.57.510.9SFT/SPM4212SPM
6M61–65larynxT1 N0
M0
middleT2 N0 M083.3316.674.7SFT/SPM124Metas?
7M61–65larynxT3 N2
M0
middleT2 N1 M01000100SPM3010SPM
8M76–80larynxT3 N0
M0
middleT2 N0 M093.756.2512.9SFT/SPM417SPM
9M41–45hypopharynxT3 N2
M0
middleT3 N1 M075252.9SFT/SPM326SPM
10M41–45hypopharynxT4 N2
M0
middleT3 N1 M092.597.4111SFT/SPM8012SPM
11M51–55hypopharynxT2 N2
M0
middleT2 N1 M01000100SPM000?
12M56–60hypopharynxT2 N0
M0
middleT2 N0 M087.112.96.3SFT/SPM8010SPM
13M61–65hypopharynxT3 N0
M0
middleT3 N2 M081.8218.184.3SFT/SPM4112SPM
14F66–70hypopharynxT3 N2
M0
middleT2 N0 M098.251.7535.7SFT/SPM519SPM
15M81–85hypopharynxT1 N3
M0
middleT2 N1 M093.756.2512.9SFT/SPM001?
16M71–75oropharynxT3 N1
M0
lowerT2 N0 M094.875.1315.5SFT/SPM404SPM
17M46–50larynxT1 N0
M0
lowerT2 N1 M01000100SPM708SPM
18M71–75larynxT2 N1
M0
lowerT2 N0 M087.512.56.5SFT/SPM9211SPM
19M41–45hypopharynxT4 N2
M0
lowerT3 N2 M01000100SPM002SPM?
20M46–50hypopharynxT3 N2
M0
lowerT2 N0 M095515.8SFT/SPM407SPM
21M51–55hypopharynxT2 N0
M0
lowerT2 N2 M01000100SPM103SPM?
  1. LOH, loss of heterozygosity; HNSCC, head and neck squamous cell carcinoma; ESCC, esophageal squamous cell carcinoma; SFT, second field tumor; SPM, second primary malignancy;?, inconclusive; SPM?, probably second primary malignancy; Metas?, probably metastasis; M, male; F, female; aAmerican Joint Committee on Cancer (AJCC) stage (7th ed); bDiscordant LOH not explained by tumor progression